You have 8 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Low density lipoprotein (LDL) cholesterol

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Categories and Attaining LDL-C Targets in Middle Eastern Adults

Not yet recruiting
  • Atherosclerotic Cardiovascular Risk
  • Low-density-lipoprotein (LDL) Cholesterol
    • (no location specified)
    Feb 16, 2023

    To Reduce the LDL-C Level in Hypercholesteremia Adult Patients, Combination for Subgroup High LDL-c Patients With Other

    Not yet recruiting
    • To Reduce the LDL-C Level in Hypercholesteremia Adult Patients
    • Combination for Subgroup High LDL-c Patients With Other Comorbidities
    • RN0191 INJECTION
    • (no location specified)
    Jun 14, 2023

    Coronary Artery Diseasse Trial in Seoul (fixed high potent statin therapy, targeted LDL-C goal statin)

    Active, not recruiting
    • Coronary Artery Diseasse
    • fixed high potent statin therapy
    • targeted LDL-C goal statin
    • Seoul, Korea, Republic of
      Division of Cardiology, Department of Internal Medicine, Yonsei
    Jul 19, 2022

    Low-density Lipoprotein Cholesterol Levels in Coronary Heart

    Completed
    Has Results
    • Hypercholesterolemia
    • (no location specified)
    Feb 7, 2022

    Serum Adropin to Testosterone and Adiponectin in Obese Men

    Completed
    • Obesity
    • Dyslipidemias
    • lipid profile: Total cholesterol (TC), triglycerides (TG), low density lipoprotein (LDL) and high density lipoprotein (HDL))
    • +3 more
    • Aswan, Egypt
      Aswan University Hospital
    Feb 14, 2022

    Atherosclerotic Cardiovascular Disease, Atherosclerotic Cardiovascular Disease Risk Equivelents, Elevated Low Density

    Active, not recruiting
    • Atherosclerotic Cardiovascular Disease
    • +2 more
    • Sale, Cheshire, United Kingdom
    • +16 more
    Jan 20, 2023

    Hyperlipidemia Trial in Changsha, Chengdu, Beijing (100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran), Placebo, 300 mg

    Completed
    • Hyperlipidemia
    • 100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran)
    • +2 more
    • Changsha, Hunan, China
    • +2 more
    Dec 2, 2021

    Improving Systolic BP and LDL-C Compared to Conventional

    Not yet recruiting
    • Hyperlipidemias
    • Hypertension
    • Rosuvastatin, Olmesartan Medoxomil
    • (no location specified)
    Jun 6, 2022

    Primary Hypercholesterolemia or Mixed Dyslipidemia Trial (Inclisiran, Matching Placebo for Inclisiran)

    Not yet recruiting
    • Primary Hypercholesterolemia or Mixed Dyslipidemia
    • (no location specified)
    May 24, 2023

    Elevated Low-Density Lipoprotein Cholesterol Trial in Herston, Adelaide, Melbourne (SNK-396 - SAD cohort, SNK-396 - MAD Cohort)

    Recruiting
    • Elevated Low-Density Lipoprotein Cholesterol
    • SNK-396 - SAD cohort
    • SNK-396 - MAD Cohort
    • Herston, Queensland, Australia
    • +2 more
    Jun 6, 2023

    Coronary Disease Trial (MK0653, ezetimibe / Duration of Treatment: 27 Weeks, MK0733, simvastatin / Duration of Treatment: 27

    Completed
    • Coronary Disease
    • MK0653, ezetimibe / Duration of Treatment: 27 Weeks
    • +2 more
    • (no location specified)
    Feb 7, 2022

    Familial Hypercholesterolaemia Trial in Czechia (Total cholesterol (TC) level test and direct Low density lipoprotein

    Recruiting
    • Familial Hypercholesterolaemia
    • Total cholesterol (TC) level test and direct Low density lipoprotein cholesterol (LDL-C) level test
    • DNA testing
    • Brno, Czechia
    • +10 more
    Nov 25, 2022

    COVID-19 Stress Syndrome, COVID-19 Vaccine Adverse Reaction, COVID-19-Associated Thromboembolism Trial in Chongqing

    Active, not recruiting
    • COVID-19 Stress Syndrome
    • +5 more
    • Atorvastatin Calcium Tablets
    • Chongqing, Chongqing, China
      Residential Address
    May 1, 2023

    Predictor of No-reflow in Diabetic Patients

    Not yet recruiting
    • Acute Myocardial Infarction (AMI)
    • 1- LDL-C (low-density lipoprotein cholesterol)| and HDL-C(high-density lipoprotein cholesterol) Ratio. 2- Glycemia will be assessed : RBS ( random blood sugar ) . 3- S
    • (no location specified)
    Apr 7, 2021

    No-Reflow Phenomenon Trial (1- LDL-C (low-density lipoprotein cholesterol)| and HDL-C(high-density lipoprotein cholesterol)

    Not yet recruiting
    • No-Reflow Phenomenon
    • 1- LDL-C (low-density lipoprotein cholesterol)| and HDL-C(high-density lipoprotein cholesterol) Ratio. 2- Glycemia will be assessed : RBS ( random blood sugar ) . 3- S
    • (no location specified)
    Apr 13, 2021

    Hyper-low-density Lipoprotein (LDL) Cholesterolemia Trial in Izumisano-shi (180mg of ETC-1002(bempedoic acid), Placebo)

    Recruiting
    • Hyper-low-density Lipoprotein (LDL) Cholesterolemia
    • 180mg of ETC-1002(bempedoic acid)
    • Placebo
    • Izumisano-shi, Japan
      Rinku General Medical Center
    Jan 4, 2023

    Prevalence of Hyperandrogenism in Type 1 Diabetes

    Recruiting
    • Type 1 Diabetes
    • +5 more
    • Clinical hyperandrogenism assessment
    • +20 more
    • Madrid, Spain
      Hospital Universitario Ramón y Cajal
    Mar 14, 2022

    Hypercholesterolemia, Familial Trial (Evolocumab, Placebo)

    Completed
    Has Results
    • Hypercholesterolemia, Familial
    • Evolocumab
    • Placebo
    • (no location specified)
    Jan 4, 2021

    Oxidized Low Density Lipoprotein Trial in Fort Lauderdale (Cardio formulation, Placebo)

    Terminated
    • Oxidized Low Density Lipoprotein
    • Cardio formulation
    • Placebo
    • Fort Lauderdale, Florida
      Lfie Extension Clinical Reseach, Inc.
    Jan 12, 2023

    Hyper-low-density Lipoprotein (LDL) Cholesterolemia Trial in Izumisano-shi (180mg of ETC-1002(bempedoic acid))

    Recruiting
    • Hyper-low-density Lipoprotein (LDL) Cholesterolemia
    • 180mg of ETC-1002(bempedoic acid)
    • Izumisano-shi, Japan
      Rinku General Medical Center
    Jan 13, 2023

    OLOMAX for Blood Pressure and Low-density Lipoprotein

    Recruiting
    • Hypertension
    • Dyslipidemias
    • Olmesartan Medoxomil/ Amlodipine Besylate/ Rosuvastatin Ca
    • Seoul, Korea, Republic of
      Seoul St.Mary's Hospital
    Dec 13, 2022

    Hypercholesterolemia Trial in Worldwide (inclisiran sodium, Placebo)

    Active, not recruiting
    • Hypercholesterolemia
    • inclisiran sodium
    • Placebo
    • Lanzhou, Gansu, China
    • +44 more
    Feb 7, 2022

    LDL Hyperlipoproteinemia, Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia, Triglyceride Storage Type I or II Disease

    Not yet recruiting
    • LDL Hyperlipoproteinemia
    • +2 more
    • omega-3 fatty acids
    • Placebo
    • Novosibirsk, Novosibisk Region, Russian Federation
      Center of New Medical Technologies
    Nov 30, 2023

    Low-density Lipoprotein Cholesterol Reduction With

    Recruiting
    • Acute Coronary Syndrome
    • Dyslipidemias
    • Banja Luka, Republic Of Srpska, Bosnia and Herzegovina
      University Clinical Centre of the Republic of Srpska
    Oct 17, 2021

    Dyslipidemia, Atherosclerosis, Acute Coronary Syndrome Trial in Dallas (RVX000222, Placebo)

    Completed
    • Dyslipidemia
    • +3 more
    • Dallas, Texas
      Covance Clinical Research Unit, Inc.
    Nov 1, 2022